Drug repositioning (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Drug repositioning" in English language version.

refsWebsite

Global rank English rank

31nih.gov

4^th place

22doi.org

2^nd place

doi.org (Global: 2^nd place; English: 2^nd place)

Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090.
Sleigh SH, Barton CL (23 August 2012). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–159. doi:10.1007/BF03256811.
Ashburn TT, Thor KB, et al. (Institute of Medicine; Board on Health Sciences Policy) (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–683. doi:10.1038/nrd1468. PMID 15286734.
Kesselheim AS, Tan YT, Avorn J (February 2015). "The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs". Health Affairs. 34 (2). Project Hope: 286–293. doi:10.1377/hlthaff.2014.1038. PMID 25646109.
Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine (2014). Drug Repurposing and Repositioning. doi:10.17226/18731. ISBN 978-0-309-30204-3. PMID 24872991.^{[page needed]}
Porta EO, Kalesh K, Steel PG (27 July 2023). "Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities". Frontiers in Pharmacology. 14 1233253. doi:10.3389/fphar.2023.1233253. PMC 10416112. PMID 37576826.
Gambino D, Otero á L (2019). "Metal Compounds in the Development of Antiparasitic Agents: Rational Design from Basic Chemistry to the Clinic". Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic. Metal Ions in Life Sciences. Vol. 19. pp. 331–358. doi:10.1515/9783110527872-019. ISBN 978-3-11-052787-2. PMID 30855114. Section 2.2.2. "Repositioning of Drugs"
Firth A, Prathapan P (2021). "Broad-spectrum therapeutics: A new antimicrobial class". Current Research in Pharmacology and Drug Discovery. 2 100011. doi:10.1016/j.crphar.2020.100011. PMC 8035643. PMID 34870144.
Rosa SG, Santos WC (2020). "Clinical trials on drug repositioning for COVID-19 treatment". Revista Panamericana de Salud Pública. 44 e40. doi:10.26633/RPSP.2020.40. PMC 7105280. PMID 32256547.
Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. (2011). "Drug Repurposing from an Academic Perspective". Drug Discovery Today: Therapeutic Strategies. 8 (3–4): 61–69. doi:10.1016/j.ddstr.2011.10.002. PMC 3285382. PMID 22368688.
Nabirotchkin S, Peluffo AE, Rinaudo P, Yu J, Hajj R, Cohen D (April 2020). "Next-generation drug repurposing using human genetics and network biology". Current Opinion in Pharmacology. 51: 78–92. doi:10.1016/j.coph.2019.12.004. PMID 31982325.
King EA, Davis JW, Degner JF (December 2019). "Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval". PLOS Genetics. 15 (12) e1008489. doi:10.1371/journal.pgen.1008489. PMC 6907751. PMID 31830040.
Kale VP, Habib H, Chitren R, Patel M, Pramanik KC, Jonnalagadda SC, et al. (January 2021). "Old drugs, new uses: Drug repurposing in hematological malignancies". Seminars in Cancer Biology. 68: 242–248. doi:10.1016/j.semcancer.2020.03.005. PMID 32151704.
Kale VP, Amin SG, Pandey MK (October 2015). "Targeting ion channels for cancer therapy by repurposing the approved drugs". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1848 (10 Pt B): 2747–2755. doi:10.1016/j.bbamem.2015.03.034. PMID 25843679.
Paranjpe MD, Taubes A, Sirota M (August 2019). "Insights into Computational Drug Repurposing for Neurodegenerative Disease". Trends in Pharmacological Sciences. 40 (8): 565–576. doi:10.1016/j.tips.2019.06.003. PMC 6771436. PMID 31326236.
Zong N, Wen A, Moon S, Fu S, Wang L, Zhao Y, et al. (June 2022). "Computational drug repurposing based on electronic health records: a scoping review". npj Digital Medicine. 5 (1) 77. doi:10.1038/s41746-022-00617-6. PMC 9198008. PMID 35701544.
Park K (June 2019). "A review of computational drug repurposing". Translational and Clinical Pharmacology. 27 (2): 59–63. doi:10.12793/tcp.2019.27.2.59. PMC 6989243. PMID 32055582.
Allegretti M, Cesta MC, Zippoli M, Beccari A, Talarico C, Mantelli F, et al. (January 2022). "Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection". Cell Death and Differentiation. 29 (1): 156–166. doi:10.1038/s41418-021-00844-6. PMC 8370058. PMID 34404919.
Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE (July 2022). "Drug repurposing: a systematic review on root causes, barriers and facilitators". BMC Health Services Research. 22 (1) 970. doi:10.1186/s12913-022-08272-z. PMC 9336118. PMID 35906687.
Liddicoat J, Liddell K, Aboy M, Wested J (August 2021). "Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the '+1' Regulatory Exclusivity". IIC - International Review of Intellectual Property and Competition Law. 52 (7): 825–851. doi:10.1007/s40319-021-01088-0.
Breckenridge A, Jacob R (January 2019). "Overcoming the legal and regulatory barriers to drug repurposing". Nature Reviews. Drug Discovery. 18 (1): 1–2. doi:10.1038/nrd.2018.92. PMID 29880920.
Fava M (February 2018). "The promise and challenges of drug repurposing in psychiatry". World Psychiatry. 17 (1): 28–29. doi:10.1002/wps.20481. PMC 5775121. PMID 29352538.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090.
Ashburn TT, Thor KB, et al. (Institute of Medicine; Board on Health Sciences Policy) (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–683. doi:10.1038/nrd1468. PMID 15286734.
Kesselheim AS, Tan YT, Avorn J (February 2015). "The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs". Health Affairs. 34 (2). Project Hope: 286–293. doi:10.1377/hlthaff.2014.1038. PMID 25646109.
Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine (2014). Drug Repurposing and Repositioning. doi:10.17226/18731. ISBN 978-0-309-30204-3. PMID 24872991.^{[page needed]}
Porta EO, Kalesh K, Steel PG (27 July 2023). "Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities". Frontiers in Pharmacology. 14 1233253. doi:10.3389/fphar.2023.1233253. PMC 10416112. PMID 37576826.
Gambino D, Otero á L (2019). "Metal Compounds in the Development of Antiparasitic Agents: Rational Design from Basic Chemistry to the Clinic". Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic. Metal Ions in Life Sciences. Vol. 19. pp. 331–358. doi:10.1515/9783110527872-019. ISBN 978-3-11-052787-2. PMID 30855114. Section 2.2.2. "Repositioning of Drugs"
Firth A, Prathapan P (2021). "Broad-spectrum therapeutics: A new antimicrobial class". Current Research in Pharmacology and Drug Discovery. 2 100011. doi:10.1016/j.crphar.2020.100011. PMC 8035643. PMID 34870144.
Rosa SG, Santos WC (2020). "Clinical trials on drug repositioning for COVID-19 treatment". Revista Panamericana de Salud Pública. 44 e40. doi:10.26633/RPSP.2020.40. PMC 7105280. PMID 32256547.
Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. (2011). "Drug Repurposing from an Academic Perspective". Drug Discovery Today: Therapeutic Strategies. 8 (3–4): 61–69. doi:10.1016/j.ddstr.2011.10.002. PMC 3285382. PMID 22368688.
Nabirotchkin S, Peluffo AE, Rinaudo P, Yu J, Hajj R, Cohen D (April 2020). "Next-generation drug repurposing using human genetics and network biology". Current Opinion in Pharmacology. 51: 78–92. doi:10.1016/j.coph.2019.12.004. PMID 31982325.
King EA, Davis JW, Degner JF (December 2019). "Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval". PLOS Genetics. 15 (12) e1008489. doi:10.1371/journal.pgen.1008489. PMC 6907751. PMID 31830040.
Kale VP, Habib H, Chitren R, Patel M, Pramanik KC, Jonnalagadda SC, et al. (January 2021). "Old drugs, new uses: Drug repurposing in hematological malignancies". Seminars in Cancer Biology. 68: 242–248. doi:10.1016/j.semcancer.2020.03.005. PMID 32151704.
Kale VP, Amin SG, Pandey MK (October 2015). "Targeting ion channels for cancer therapy by repurposing the approved drugs". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1848 (10 Pt B): 2747–2755. doi:10.1016/j.bbamem.2015.03.034. PMID 25843679.
Paranjpe MD, Taubes A, Sirota M (August 2019). "Insights into Computational Drug Repurposing for Neurodegenerative Disease". Trends in Pharmacological Sciences. 40 (8): 565–576. doi:10.1016/j.tips.2019.06.003. PMC 6771436. PMID 31326236.
Zong N, Wen A, Moon S, Fu S, Wang L, Zhao Y, et al. (June 2022). "Computational drug repurposing based on electronic health records: a scoping review". npj Digital Medicine. 5 (1) 77. doi:10.1038/s41746-022-00617-6. PMC 9198008. PMID 35701544.
Park K (June 2019). "A review of computational drug repurposing". Translational and Clinical Pharmacology. 27 (2): 59–63. doi:10.12793/tcp.2019.27.2.59. PMC 6989243. PMID 32055582.
Allegretti M, Cesta MC, Zippoli M, Beccari A, Talarico C, Mantelli F, et al. (January 2022). "Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection". Cell Death and Differentiation. 29 (1): 156–166. doi:10.1038/s41418-021-00844-6. PMC 8370058. PMID 34404919.
Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE (July 2022). "Drug repurposing: a systematic review on root causes, barriers and facilitators". BMC Health Services Research. 22 (1) 970. doi:10.1186/s12913-022-08272-z. PMC 9336118. PMID 35906687.
Breckenridge A, Jacob R (January 2019). "Overcoming the legal and regulatory barriers to drug repurposing". Nature Reviews. Drug Discovery. 18 (1): 1–2. doi:10.1038/nrd.2018.92. PMID 29880920.
Fava M (February 2018). "The promise and challenges of drug repurposing in psychiatry". World Psychiatry. 17 (1): 28–29. doi:10.1002/wps.20481. PMC 5775121. PMID 29352538.

ncbi.nlm.nih.gov

Porta EO, Kalesh K, Steel PG (27 July 2023). "Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities". Frontiers in Pharmacology. 14 1233253. doi:10.3389/fphar.2023.1233253. PMC 10416112. PMID 37576826.
Firth A, Prathapan P (2021). "Broad-spectrum therapeutics: A new antimicrobial class". Current Research in Pharmacology and Drug Discovery. 2 100011. doi:10.1016/j.crphar.2020.100011. PMC 8035643. PMID 34870144.
Rosa SG, Santos WC (2020). "Clinical trials on drug repositioning for COVID-19 treatment". Revista Panamericana de Salud Pública. 44 e40. doi:10.26633/RPSP.2020.40. PMC 7105280. PMID 32256547.
Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. (2011). "Drug Repurposing from an Academic Perspective". Drug Discovery Today: Therapeutic Strategies. 8 (3–4): 61–69. doi:10.1016/j.ddstr.2011.10.002. PMC 3285382. PMID 22368688.
King EA, Davis JW, Degner JF (December 2019). "Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval". PLOS Genetics. 15 (12) e1008489. doi:10.1371/journal.pgen.1008489. PMC 6907751. PMID 31830040.
Paranjpe MD, Taubes A, Sirota M (August 2019). "Insights into Computational Drug Repurposing for Neurodegenerative Disease". Trends in Pharmacological Sciences. 40 (8): 565–576. doi:10.1016/j.tips.2019.06.003. PMC 6771436. PMID 31326236.
Zong N, Wen A, Moon S, Fu S, Wang L, Zhao Y, et al. (June 2022). "Computational drug repurposing based on electronic health records: a scoping review". npj Digital Medicine. 5 (1) 77. doi:10.1038/s41746-022-00617-6. PMC 9198008. PMID 35701544.
Park K (June 2019). "A review of computational drug repurposing". Translational and Clinical Pharmacology. 27 (2): 59–63. doi:10.12793/tcp.2019.27.2.59. PMC 6989243. PMID 32055582.
Allegretti M, Cesta MC, Zippoli M, Beccari A, Talarico C, Mantelli F, et al. (January 2022). "Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection". Cell Death and Differentiation. 29 (1): 156–166. doi:10.1038/s41418-021-00844-6. PMC 8370058. PMID 34404919.
Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE (July 2022). "Drug repurposing: a systematic review on root causes, barriers and facilitators". BMC Health Services Research. 22 (1) 970. doi:10.1186/s12913-022-08272-z. PMC 9336118. PMID 35906687.
Fava M (February 2018). "The promise and challenges of drug repurposing in psychiatry". World Psychiatry. 17 (1): 28–29. doi:10.1002/wps.20481. PMC 5775121. PMID 29352538.

Drug repositioning (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

doi.org (Global: 2^nd place; English: 2^nd place)

nih.gov (Global: 4^th place; English: 4^th place)